Similar articles

• Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

  Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A. Kuroda J, et al. Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14907-12. doi: 10.1073/pnas.0606176103. Epub 2006 Sep 22. Proc Natl Acad Sci U S A. 2006. PMID: 16997913 Free PMC article.
• Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.

  Härtel N, Klag T, Hanfstein B, Mueller MC, Schenk T, Erben P, Hochhaus A, La Rosée P. Härtel N, et al. J Cancer Res Clin Oncol. 2012 Feb;138(2):203-12. doi: 10.1007/s00432-011-1086-x. Epub 2011 Nov 17. J Cancer Res Clin Oncol. 2012. PMID: 22089930 Free PMC article.
• Chronic myelogenous leukemia: molecular and cellular aspects.

  Pasternak G, Hochhaus A, Schultheis B, Hehlmann R. Pasternak G, et al. J Cancer Res Clin Oncol. 1998;124(12):643-60. doi: 10.1007/s004320050228. J Cancer Res Clin Oncol. 1998. PMID: 9879825 Free PMC article. Review.
• 3D-QSAR Design of New Bcr-Abl Inhibitors Based on Purine Scaffold and Cytotoxicity Studies on CML Cell Lines Sensitive and Resistant to Imatinib.

  Cabezas D, Delgado T, Sepúlveda G, Krňávková P, Vojáčková V, Kryštof V, Strnad M, Silva NI, Echeverría J, Espinosa-Bustos C, Mellado G, Luo J, Mella J, Salas CO. Cabezas D, et al. Pharmaceuticals (Basel). 2025 Jun 19;18(6):925. doi: 10.3390/ph18060925. Pharmaceuticals (Basel). 2025. PMID: 40573320 Free PMC article.
• Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.

  Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K. Rogers G, et al. Health Technol Assess. 2012;16(22):1-410. doi: 10.3310/hta16220. Health Technol Assess. 2012. PMID: 22551803 Free PMC article.